Brokerages Set Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Target Price at $55.50

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has been assigned a consensus recommendation of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $55.50.

A number of research firms have recently commented on TVRD. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Tuesday, October 14th. Piper Sandler cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Barclays set a $5.00 price target on shares of Tvardi Therapeutics and gave the company an “equal weight” rating in a report on Monday, October 13th. Raymond James Financial cut shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Finally, Wall Street Zen downgraded Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 18th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of TVRD. Slate Path Capital LP bought a new position in shares of Tvardi Therapeutics in the second quarter worth approximately $16,427,000. 683 Capital Management LLC purchased a new position in Tvardi Therapeutics in the 2nd quarter worth approximately $4,107,000. Geode Capital Management LLC bought a new position in shares of Tvardi Therapeutics in the 2nd quarter worth $2,617,000. Marshall Wace LLP purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter valued at $583,000. Finally, Bank of America Corp DE bought a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth $399,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Stock Down 2.5%

Tvardi Therapeutics stock opened at $4.66 on Tuesday. The company has a market capitalization of $43.71 million, a price-to-earnings ratio of -0.21 and a beta of 0.24. Tvardi Therapeutics has a one year low of $4.48 and a one year high of $43.65. The stock has a fifty day moving average of $26.70.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.49). Tvardi Therapeutics had a negative return on equity of 565.83% and a negative net margin of 678.79%.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.